BRCA1 and breast carcinoma: In the future, patients with advanced breast cancer with BRCA1/2 mutation in China and the United States will be more inclined to choose talazoparib as the first choice of treatment, rather than the traditional Eribulin, capecitabine, gemcitabine, and vinorelbine treatment.